Apyx Medical (APYX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.67%. A quarter ago, it was expected that this medical device maker would post a loss of $0.18 per share when it actually produced a loss of $0.19, delivering a surprise of -5.56%.Over the last four quarters, the company has ...

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this "Agreement") is dated as of November 7, 2024, between Apyx Medical Corporation, a Delaware corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser" and collectively the "Purchasers"). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as ...

CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company’s common stock at a purchase price of $1.18 per share and pre-funded warrants to pu ...

Strengthened balance sheet with a common stock registered direct offering with gross proceeds of approximately $7.0 million; and amended revenue covenants for the Company’s credit agreement with PerceptiveAnnounces cost savings restructuring program to better focus, optimize and streamline operations, including a nearly 25% reduction in U.S. workforce Announces 9% overall growth in single-use handpiece revenue and 15% growth in the U.S.Management to host a conference call today at 8:00 a.m. ET CLEARWATER, F ...

Company Overview - Apyx Medical Corporation is an advanced energy technology company focused on innovative products, including its Helium Plasma Platform Technology marketed as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market [2] - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical documents, showcasing the company's commitment to clinical validation [2] Financial Results Announcement - Apyx Medical will release its financial results for the third quarter of fiscal year 2024 before the market opens on November 8, 2024 [1] - Management will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the quarterly results and conduct a question-and-answer session [1] - Interested parties can access the call by phone or through a live webcast, which will also be archived for future reference [1]

Apyx Medical (APYX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing ear ...

Group 1 - Renuvion has been recognized as the 1 trusted body contouring technology by plastic and cosmetic surgeons in an independent survey conducted by Wakefield Research, highlighting its effectiveness in targeting loose skin [1][3] - The technology is the first and only FDA-cleared device for contracting subcutaneous tissue and is preferred by 4 out of 5 surgeons for use after liposuction, which was the most common cosmetic surgical procedure in 2023 with nearly 2.3 million performed [3] - Apyx Medical has secured four FDA 510(k) clearances in the past two years, demonstrating its commitment to evidence-based outcomes through advanced technology [2] Group 2 - Renuvion has treated over 350,000 patients since its market launch, aiming to improve physical, mental, and emotional well-being [2] - The company emphasizes the importance of trust and results in the plastic surgery industry, supported by over 90 clinical papers and peer-reviewed studies [2] - Apyx Medical Corporation specializes in advanced energy technology, with products marketed as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market, providing controlled heat to tissue for desired surgical outcomes [4]

Apyx Medical Corporation (NASDAQ:APYX) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matthew Hill - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Frank Takkinen - Lake Street Capitals George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. At this ti ...

Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.56%. A quarter ago, it was expected that this medical device maker would post a loss of $0.18 per share when it actually produced a loss of $0.22, delivering a surprise of -22.22%.Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock APYX Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-3 ...